Fibrinogen metabolism in cyanoti congenital heart disease

Area of Science:

• Pediatric Cardiology
• Hematology
• Biochemistry

Background:

• Cyanotic congenital heart disease (CCHD) is associated with complex physiological changes.
• Understanding coagulation factor metabolism is crucial in managing CCHD patients.
• Fibrinogen plays a key role in hemostasis and thrombosis.

Purpose of the Study:

• To investigate the in vivo kinetics and metabolism of fibrinogen in children with CCHD.
• To determine if altered fibrinogen turnover is linked to the disease state.

Main Methods:

• Fibrinogen was labelled with radioactive iodine (125I).
• In vivo kinetic studies were performed in pediatric patients with CCHD.
• Plasma fibrinogen pool, half-life, and fractional catabolic rate were measured.
• The effect of heparin (anticoagulation) and epsilon-aminocaproic acid (fibrinolysis inhibition) was assessed.

Main Results:

• Patients with CCHD exhibited a significantly reduced plasma fibrinogen pool and shortened fibrinogen half-life.
• The fractional catabolic rate of fibrinogen was significantly increased in CCHD patients.
• Average plasma fibrinogen and absolute catabolic rate did not differ from controls.
• Anticoagulation with heparin corrected the shortened fibrinogen half-life, suggesting consumption.
• Inhibition of fibrinolysis with epsilon-aminocaproic acid had variable effects on fibrinogen half-life.

Conclusions:

• Children with CCHD experience accelerated fibrinogen consumption, likely due to chronic disseminated intravascular coagulation (DIC).
• The findings highlight a prothrombotic state in CCHD related to fibrinogen turnover.
• Therapeutic strategies targeting coagulation pathways may be beneficial in CCHD management.